Endocrine Society Sets the Bar for Diagnosing Low Testosterone
The Endocrine Society's 2018 guidelines require both persistent symptoms and two confirmed low morning testosterone readings before diagnosis, raising the standard for evidence-based hormonal care.
Read the original article at The Journal of Clinical Endocrinology & MetabolismKairos™'s Take
Kairos™'s perspective on this story
In 2018, the Endocrine Society published its updated Clinical Practice Guideline for testosterone therapy in men with hypogonadism, and its central message was clear: do not diagnose low testosterone based on a single lab draw or vague symptoms alone. A valid diagnosis requires symptoms and signs consistent with testosterone deficiency alongside at least two measurements of unequivocally low morning serum testosterone concentrations.
The guideline specifies that total testosterone should be measured first, with free testosterone assessed when total levels are near the lower boundary or when SHBG abnormalities are suspected. Free testosterone should ideally be measured by equilibrium dialysis or calculated using validated formulas that account for total testosterone, SHBG, and albumin. The emphasis on morning testing is critical because testosterone follows a diurnal pattern, peaking in the early hours and declining throughout the day.
The guideline also draws a line between primary hypogonadism, where the testes themselves are failing, and secondary hypogonadism, where the problem originates in the pituitary or hypothalamus. Distinguishing between these requires measuring LH and FSH concentrations, a step that many clinicians skip but that fundamentally changes the treatment approach.
Importantly, the Endocrine Society recommends against routine screening of men in the general population. Testing should be driven by clinical suspicion, not by marketing. This makes it even more important for men who do have symptoms to bring organized, longitudinal health data to their provider rather than relying on a single conversation to trigger the right workup.
The Tracking Connection
Kairos™ helps men meet the evidentiary standard these guidelines demand. By tracking symptoms, energy levels, mood, and prior lab results over time, Kairos creates a clinical narrative that makes it easier for providers to identify who genuinely needs testing and follow through with the two-measurement protocol. Instead of walking into an appointment with a hunch, you walk in with a data-backed case.
Ready to start tracking?
Kairos™ tracks, scores, and interprets the symptoms of midlife hormonal change — for both women and men.
Get StartedMore from the newsroom
The Vicious Cycle: How Obesity and Low Testosterone Reinforce Each Other
A clinical review finds obesity increases hypogonadism risk up to 8.7-fold, while low testosterone promotes further fat accumulation, creating a self-reinforcing metabolic trap that requires integrated monitoring to break.
JAMA Psychiatry: Testosterone Treatment Linked to 130% Greater Improvement in Depression
A meta-analysis of 27 clinical trials found that men receiving testosterone treatment were 130% more likely to see significant improvement in depressive symptoms, even in some men with normal testosterone levels.
Exercise and Testosterone: The Evidence Is More Nuanced Than Headlines Suggest
A systematic review of 11 RCTs found that exercise training had a negligible effect on resting testosterone in insufficiently active men, challenging the popular narrative that working out reliably boosts T levels.